*Corresponding Author:
Jiuwei Cui
Department of Oncology, Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin Province 130021, China
E-mail:
cuijw@jlu.edu.cn
This article was originally published in a special issue, “Drug Discovery and Repositioning Studies in Biopharmaceutical Sciences”
Indian J Pharm Sci 2024:86(4) Spl Issue “326-333”

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms

Abstract

Ring finger protein 146, an E3 ubiquitin ligase, regulates breast cancer development, metastasis and drug resistance. E3 ubiquitin ligase is an indispensable class of enzymes in the ubiquitin-proteasome system, which can be divided into HECT E3s, U-box E3s and ring E3s. Genome-wide association analyses have revealed the association between the ring finger protein 146 rs2180341 single nucleotide polymorphism and breast cancer risk in Ashkenazi Jewish people but not in Southern Chinese individuals. Herein, A retrospective case-control study of 828 breast cancer patients and 905 healthy controls was conducted to examine this association in Northern Chinese. Deoxyribonucleic acid from peripheral blood was sequenced to determine genotypes. We analyzed the association of the ring finger protein 146 rs2180341 single nucleotide polymorphism with breast cancer risk using odds ratios with binary logistic regression and between the single nucleotide polymorphism and clinic pathological breast cancer characteristics using Pearson’s chi-square or Fisher’s exact tests. Survival analyses were performed using the Kaplan-Meier method. In the codominant model, the ring finger protein 146 rs2180341 single nucleotide polymorphism and breast cancer risk were correlated. Our results showed that, compared with individuals with the ring finger protein 146 rs2180341 AA genotype, those with the GG genotype had an odds ratio of 1.932 (95 % confidence interval, 1.320-2.829, p=0.001) for developing breast cancer. No significant associations were found between the single nucleotide polymorphism and clinical characteristics or disease-free or overall survival. In conclusion, this single nucleotide polymorphism is related to breast cancer susceptibility but not with breast cancer clinic pathological characteristics or prognosis in Northern Chinese individuals.

Keywords

Ring finger protein 146 rs2180341, single nucleotide polymorphism, breast cancer, metastasis, drug resistance

According to the International Agency for Research on Cancer, Breast Cancer (BC) has now surpassed lung cancer to become the world’s number one cancer[1,2]. In 2030, the incidence of BC in China is expected to reach 234 000 cases[3]. The Ring Finger Protein 146 (RNF146) rs2180341 Single Nucleotide Polymorphism (SNP) is the most common genetic variant and can be used to predict the risk and prognosis of tumors, providing a molecular basis for the occurrence and development of BC[4].

RNF146, also known as dactylidin, is located in 6q22.1-q22.33 and contains five exons[5]. RNF146 encodes an amino terminal ring finger (propyne (C3HC4) ring finger) of a ubiquitin protein ligase (E3) containing WWE and the N-terminal ring finger domain[6-8]. The Wnt/β-catenin signaling pathway is of vital importance in both embryo and organ development; however, it is abnormally activated in cancerous tissues[9-11]. RNF146 is genetically amplified in ovarian, breast and colorectal cancers and is regulated by the Wnt signaling pathway[12-15]. RNF146 binds to the Poly ADP-Ribose (PAR)- ribosylated axin through its PAR-binding domain in the WWE domain and exerts its role as an E3 ubiquitin ligase[16,17]. RNF146 can recruit E2 ubiquitin-conjugating enzymes, degrade axin and the β-catenin degradation complex and accumulate β-catenin in the cytoplasm, thereby activating the Wnt signaling pathway[18-20]. Additionally, RNF146 is predominantly involved in the metastasis, development, drug resistance and invasion of BC[21].

A previous study showed that the RNF146 rs2180341 SNP is related to proliferation, metastasis and drug resistance in BC. The association between RNF146 rs2180341 SNP and BC susceptibility was first observed in Ashkenazi Jews (AJ). The findings of Kirchhoff et al.[22], who performed a follow-up study with 1953 patients with BC and 1467 controls of European ancestry, further supported this. However, no relationship was observed in subsequent Indian[23,24] and Southern Chinese[25] population studies. To further investigate this, we analyzed the relation between the RNF146 rs2180341 SNP and the susceptibility and prognosis of BC in China[26].

Materials and Methods

Study design:

Choice and description of participants: The association of the RNF146 rs2180341 SNP with BC in a Northern Chinese population was investigated using a retrospective case-control study. From April 2013 to September 2016, 828 patients with BC and 905 age-matched healthy controls were enrolled at Jilin University First Affiliated Hospital (Changchun City, Jilin Province, China). A median follow-up time was 6.7 y. The features of patients are obtained from their records. A pathology diagnosis of early cancer in females was the inclusion criteria.

RNF146 rs2180341 SNP genotyping: Peripheral blood samples were extracted to obtain Deoxyribonucleic Acid (DNA), and genotypes were detected using a matrix-assisted laser desorption ionization-time of flight mass spectrometer (Agena, San Diego, California, United States of America (USA)). SNP genotyping without knowing the case status. 15 % of the samples were tested interactively and reproducibility was 99.7 %.

Statistical analysis:

Statistical Package for the Social Sciences (SPSS) and online SNP stats developed by Catala d’Oncologia Institute were used to analyze the risk of BC. Based on Odds Ratio (OR) and 95 % Confidence Interval (CI), RNF146 rs2180341 SNP was associated with BC risk, and was analyzed by binary logistic regression. Kaplan-Meier and univariate Cox models were used to analyze the effects of RNF146 rs2180341 SNP on Disease-Free Survival (DFS) and Overall Survival (OS). Statistical significance was set at p≤0.05 for all statistical tests, and all the tests were assumed to be two-sided.

Results and Discussion

All the controls first underwent a physical examination at our hospital and were confirmed to not have a familial history of cancer. The median age of the control group was 38 y (range of 32 y-53 y). The case group included 398 premenopausal and 430 postmenopausal, with a median age of 51 y (ranging from 44 y to 58 y old), among whom 32 patients had a family history of cancer. Among 828 cases of BC, 793 cases have invasive ductal carcinoma, and 35 cases have other diseases. A detailed description of the patient’s characteristics is provided in Table 1. Genotype distribution of the RNF146 rs2180341 SNP was not significantly different between the case and control groups (Table 2). Three genetic models showed that the SNP rs2180341 in RNF146 was associated with increased BC risk. Codominant genetic models had the lowest Akaike information criterion, which was used to select the optimal genetic model. Compared with AA, the BC of rs2180341 GG is 1.932 (95 % CI, 1.320-2.829, p=0.001). Compared with AA, the genotype of rs2180341 GA also increased the risk of BC (OR, 1.168; 95 % CI, 0.944-1.446, p=0.153). In the implicit model, compared with AA, the OR of rs2180341 GG to BC development is 1.810 (95 % CI, 1.250-2.621, p=0.002). In the dominance model, compared with AA, rs2180341 GG also increases the risk of BC (OR, 1.277; 95 % CI is 1.043-1.563, p=0.018). In the hyper dominant model, RNF146 rs2180341 was not associated with BC risk (Table 3 and fig. 1).

Characteristic Cases no (%)
Age (years)
35 52 (6.28)
>35 776 (93.72)
Menstrual status
Premenopause 398 (48.07)
Postmenopause 430 (51.93)
Family history
Negative 796 (96.14)
Positive 32 (3.86)
Pathological type
Infiltrating ductal carcinoma 793 (95.77)
Other types 35 (4.23)
Histological grade
I 31 (3.74)
II 511 (61.71)
III 286 (34.54)
Tumor size
T1 422 (50.97)
T2 365 (44.08)
T3 27 (3.26)
T4 14 (1.69)
Lymph node
N0 396 (47.83)
N1 285 (34.42)
N2 101 (12.20)
N3 46 (5.58)
Lymphovascular invasion
Negative 471 (56.88)
Positive 357 (43.12)
Perineural invasion
Negative 689 (83.21)
Positive 139 (16.79)
Clinical stage
I 243 (29.35)
II 415 (50.12)
III 159 (19.20)
IV 11 (1.33)
Total 828 (100.00)

Table 1: Clinicopathological Characteristics

SNPs Cases Controls
1H0 1He χ2 p 1H0 1He χ2 p
rs 2180341 0.3804 0.4152 5.8037 0.016 0.3856 0.3797 0.2248 0.6354

Table 2: Hardy-Weinberg Balance Test

SNP Genotype Model Cases no (%) Controls no (%) OR (95 % CI) p AIC
rs 2180341 AA Codominant 427 (51.57) 500 (55.25) 1.000 0.003 2183.1
GA 315 (38.04) 349 (38.56) 1.168 (0.944-1.446) 0.153
GG 86 (10.39) 56 (6.19) 1.932 (1.320-2.829) 0.001
AA Dominant 427 (51.57) 500 (55.25) 1.000 0.018 2187.5
GA/GG 401 (48.43) 405 (44.75) 1.277 (1.043-1.563)
AA/GA Recessive 742 (89.61) 849 (93.81) 1.000 0.002 2184
GG 86 (10.39) 56 (6.19) 1.810 (1.250-2.621)
AA/GG Overdominant 513 (61.96) 556 (61.44) 1.000 0.526 2193.9
GA 315 (38.04) 349 (38.56) 1.069 (0.869-1.315)
A - 1169 (70.59) 1349 (74.53) 1.000 <0.001 -
G - 487 (29.41) 461 (25.47) 1.334 (1.138-1.565)

Table 3: Association between Hotair rs 2180341 Polymorphism and Bc Risk

pharmaceutical-sciences-patients

Fig. 1: (A): DFS and (B): OS of BC patients with different HOTAIR rs2180341 genotypes Note: There was no statistical difference among the three curves of DFS (p=0.39) and OS (p=0.19), (Image): rs2180341=A/A; (Image): rs2180341=G/A and (Image): rs2180341=G/G

Genotype distribution of the RNF146 rs2180341 SNP was not significantly different between the case and control groups (Table 4). Three genetic models showed that the SNP rs2180341 in RNF146 was associated with increased BC risk. Codominant genetic models had the lowest Akaike information criterion, which was used to select the optimal genetic model. Compared with AA, the BC of rs2180341 GG is 1.932 (95 % CI, 1.320-2.829, p=0.001). Compared with AA, the genotype of rs2180341 GA also increased the risk of BC (OR, 1.168; 95 % CI, 0.944-1.446, p=0.153). In the implicit model, compared with AA, the OR of rs2180341 GG to BC development is 1.810 (95 % CI, 1.250-2.621, p=0.002). In the dominance model, compared with AA, rs2180341 GG also increases the risk of BC (OR, 1.277; 95 % CI is 1.043-1.563, p=0.018). In the hyper dominant model, RNF146 rs2180341 was not associated with BC risk (Table 5).

Characteristic Grouping rs genotype 2180341 χ2 p
AA, n (%) GA, n (%) GG, n (%)
ER Negative 107 (25.06) 81 (25.72) 26 (30.23) 4.975 0.547
<30 % 29 (6.79) 16 (5.08) 9 (10.47)
30 %-50 % 21 (4.92) 15 (4.76) 3 (3.49)
>50 % 270 (63.23) 203 (64.44) 48 (55.81)
PR Negative 170 (39.81) 119 (37.78) 40 (46.51) 4.105 0.663
<30 % 50 (11.71) 40 (12.70) 11 (12.79)
30 %-50 % 41 (9.60) 33 (10.48) 4 (4.65)
>50 % 166 (38.88) 123 (39.04) 31 (36.05)
HER-2 Negative 286 (66.98) 218 (69.21) 59 (68.60) 0.43 0.807
Positive 141 (33.02) 97 (30.79) 27 (31.40)
Ki-67 <14 % 73 (17.10) 46 (14.60) 12 (13.95) 2.912 0.573
14 %-30 % 96 (22.48) 79 (25.08) 16 (18.60)
>30 % 258 (60.42) 190 (60.32) 58 (67.45)
Molecular type Luminal A 57 (13.35) 38 (12.06) 9 (10.47) 1.925 0.926
Luminal B 267 (62.53) 201 (63.81) 52 (60.47)
HER2 52 (12.18) 37 (11.75) 14 (16.28)
Triple negative 51 (11.94) 39 (12.38) 11 (12.78)
Lymphovascular invasion Negative 242 (56.67) 174 (55.24) 55 (63.95) 2.108 0.349
Positive 185 (43.33) 141 (44.76) 31 (36.05)
Lymph node N0 206 (48.24) 146 (46.35) 44 (51.16) 8.503 0.204
N1 143 (33.49) 114 (36.19) 28 (32.56)
N2 55 (12.88) 41 (13.02) 5 (5.81)
N3 23 (5.39) 14 (4.44) 9 (10.47)
Tumor size T1 222 (51.99) 159 (50.48) 41 (47.67) 7.826 0.251
T2 181 (42.39) 146 (46.35) 38 (44.19)
T3 14 (3.28) 9 (2.86) 4 (4.65)
T4 10 (2.34) 1 (0.31) 3 (3.49)
Menstrual status Premenopause 198 (46.37) 154 (48.89) 46 (53.49) 1.59 0.451
Postmenopause 229 (53.63) 161 (51.11) 40 (46.51)
Family history Negative 411 96.25 299 (94.92) 86 (100.00) 4.724 0.094
Positive 16 (3.75) 16 (5.08) 0 (0.00)
Pathological type Infiltrating ductal carcinoma 409 (95.78) 299 (94.92) 85 (98.84) 2.56 0.278
Other types histological grade 18 (4.22) 16 (5.08) 1 (1.16)
Histological grade I 17 (3.98) 13 (4.13) 1 (1.16) 3.097 0.542
II 260 (60.89) 200 (63.49) 51 (59.30)
III 150 (35.13) 102 (32.38) 34 (39.54)
Perineural invasion Negative 350 (81.97) 266 (84.44) 73 (84.88) 0.988 0.61
Positive 77 (18.03) 49 (15.56) 13 (15.12)
Clinical stage Stage I 133 (31.15) 84 (26.67) 26 (30.23) 4.254 0.642
Stage II 204 (47.78) 169 (53.65) 42 (48.84)
Stage III 86 (20.14) 57 (18.10) 16 (18.60)
Stage IV 4 (0.93) 5 (1.58) 2 (2.33)
Total 427 (100.00) 315 (100.00) 86 (100.00)

Table 4: Association between Rnf146 Rs2180341 Polymorphism and Bc Clinical Characteristics

Indicator B SE Wald Df HR (95 % CI) p
DFS AA 0.691 2 0.708
GA -0.074 0.213 0.119 1 0.929 (0.612-1.411) 0.73
GG 0.176 0.293 0.363 1 1.193 (0.672-2.118) 0.547
OS AA 1.695 2 0.428
GA 0.071 0.353 0.040 1 1.073 (0.538-2.143) 0.841
GG 0.588 0.46 1.635 1 1.801 (0.731-4.436) 0.201

Table 5: The Cox Model Result of Genotype

RNF146 is an E3 ubiquitin ligase that downregulates the expression of axin while also inducing the expression of Beta (β)-catenin and increasing its nuclear accumulation[27,28]. Studies confirm that when β-catenin enters the nucleus, it loses its function as a cell adhesion molecule, positively regulates the Wnt signaling pathway, and activates the proliferation, invasion and metastasis of BC[29]. rs2180341 (A>G) is in the intron region of RNF146 and its expression is increased in the GG genotype.

Previous studies that examined the association of the RNF146 rs2180341 SNP with BC susceptibility produced controversial results. In our study, we found that RNF146 rs2180341 SNP increased the risk of BC, which was consistent with the results of Gold et al.[18] for an AJ population and Kirchhoff et al.[22] for a non-AJ population with predominantly European ancestry. Other studies have found no relationship between ethnicity and birth rate among southern Chinese[25], European[30], Cypriot[31] or Chinese Singaporean[32] populations. Genetic and environmental variations may be responsible for the difference in results. The results of the present study, which focused on the Northern and Southern Chinese populations, indicate that unique genetic backgrounds and living environments with different geographical distributions in the same area may affect the occurrence and development of tumors. The median age of the Northern Chinese population was lower than that of the Southern Chinese population and the environment influenced individual genes. A comparison of the results from this study with previous studies is provided in Table 6.

Author Date of publication Ethnicity Median age of case group Number of cases Number of controls Source of control Assay methods OR (p)
Gold et al. 2008 AJ 55 950 979 Hospital Taq man SNP genotyping 1.412.9×10-8
Kirchhoff et al. 2009 AJ and European American (non-AJ) _ 1953 1467 Population Taq man SNP genotyping 1.18, p=0.0083
Kirchhoff et al. 2009 AJ and European American (non-AJ) _ 1953 1467 Population Taq man SNP genotyping 1.18, p=0.0083
Long et al. 2010 Southern Chinese 49.3 and 53.9 6498 3999 Population Mass array system Taq man SNP genotyping 0.94, p=0.13
Campa et al. 2011 BPC3 (83 % European descent and Latino) 62.39 8576 11 892 Population Taq man SNP genotyping 0.95, p=0.11
Loizidou et al. 2011 Cypriot population _ 1109 1177 Population Taq man SNP genotyping 1.07, p=0.34
Kirchhoff et al. 2012 BCAC (88.9 % European and 9 % Asian) 53.1 31 428 34 700 Population Taq man SNP genotyping 1.03, p=0.031
Lee et al. 2014 Singapore Chinese 54.9 411 1212 Population Mass array system 1.09, p=0.365
Nagrani et al. 2017 Western Indian 46 1204 1212 Hospital Taq man SNP genotyping 0.95, p=0.408
Present study 2021 Northern Chinese 51 828 905 Hospital Mass array system 1.932, p=0.001

Table 6: Comparison of our Results and those of Previous Studies

Kirchhoff et al.[22] found that the RNF146 rs2180341 SNP increased the risk of ER-positive BC (OR, 1.35; 95 % CI, 1.20-1.51, p=2.2×10-5). In contrast, this study found no evidence of a similar relationship in the Northern Chinese population. Furthermore, no relationship was observed between the RNF146 rs2180341 SNP and other clinicopathological characteristics such as menstrual status, pathological type and family history[33].

BC was the first cancer associated with Wnt signaling, and RNF146-regulated activation of Wnt signaling is recognized as a key factor in metastasis, proliferation, drug resistance, immune microenvironment regulation and stem cell maintenance in BC[34-36]. However, we did not find any significant association between the RNF146 rs2180341 SNP and DFS, and OS of BC in this study. The rs2180341 GG genotype was associated with a relatively poor DFS and OS of BC. This may be owing to the short duration of follow-up and small sample size of individuals with the GG genotype. To address this limitation, a large number of individuals with the GG phenotype should be enrolled and studied in future studies.

The results of this study show that the RNF146 rs2180341 SNP increases the risk of BC in the Northern Chinese population and should be investigated in greater detail in the future. Owing to the differences in the living environments and genetic backgrounds of populations in different regions, indepth studies with large sample sizes are warranted in other regions.

Ethical approval:

The research was approved by the Ethics Committee of the First Affiliated Hospital of Jilin University (Approval No: 2014-031), which was conducted according to relevant guidelines and Helsiniki’s statement. All participants provided written informed consent.

Funding:

This study was financially supported by the Natural Science Foundation of Jilin Province (Grant No: 2020J053).

Conflict of interests:

The authors declared no conflict of interests.

References